REDUCE LAP-HF II

What is the purpose of this trial?

The primary objective of this randomized controlled clinical trial is to evaluate the clinical efficacy and safety of the IASD System II in symptomatic heart failure patients with an LV ejection fraction ≥40%, and elevated left sided filling pressures despite standard Guideline Directed Medical Therapy (GDMT).


Participation Guidelines

Ages: 40 years and older

Gender: Both


Corvia Medical, Inc.

Dates: 07/26/2017 - 09/30/2019

Last Updated: 07/30/2017

Study HIC#: 2000020740

Get Involved

For more information about this study, contact:
Bemen Habashi
203-737-1330
bemen.habashi@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image

Investigators

Sub-Investigators